🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: darunavir with ritonavir and fixed-dose viread+emtricitabine daily

Found 16 matching trials

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

PHASE4

The goal of this clinical study is to provide continued access to the study...

Status

Recruiting

Location

Helios Salud

Start Date

2024-08-27

Trial ID

NCT06337032

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

PHASE3

The primary objective of this study is to evaluate the efficacy of switchin...

Status

Completed

Location

University of Alabama at Birmingham

Start Date

2018-08-28

Trial ID

NCT03631732

Treatments Being Tested

B/F/TAF NRTIs Third Agent

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

PHASE3

This study will evaluate the non-inferiority of Stribild® (elvitegravir/cob...

Status

Completed

Location

Spectrum Medical Group

Start Date

2011-11

Trial ID

NCT01475838

Treatments Being Tested

PI RTV FTC/TDF Stribild

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

PHASE3

The purpose of this randomized, open-label, multicenter, active-controlled ...

Status

Completed

Location

University of Alabama - Birmingham

Start Date

2010-11

Trial ID

NCT01252940

Treatments Being Tested

FTC/RPV/TDF PI RTV NRTIs

Interaction With HIV Antiretroviral Agents

PHASE1

To investigate the pharmacokinetic drug-drug interaction potential of fixed...

Status

Completed

Location

Multiple Locations

Start Date

2016-02-23

Trial ID

NCT02556268

Treatments Being Tested

Riociguat (Adempas, BAY 63-2521)ATRIPLA COMPLERA STRIBILD TRIUMEQ Antiretroviral protease inhibitor

Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts

PHASE4

A phase IV, prospective, multicenter , randomized open label, 48 weeks stud...

Status

Completed

Location

Hopital Zobda Quitman

Start Date

2011-02-23

Trial ID

NCT01928407

Treatments Being Tested

DARUNAVIR ATAZANAVIR

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

PHASE3

The primary purpose of this study is to assess the rate of early discontinu...

Status

Completed

Location

Multiple Locations

Start Date

2011-11-25

Trial ID

NCT01516970

Treatments Being Tested

Darunavir/Ritonavir (DRV/r)Lopinavir in fixed combination with Ritonavir Zidovudine NRTIs Efavirenz

Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa

PHASE4

The purpose of this study is to compare two different combination anti-HIV ...

Status

Completed

Location

Birmingham Heartlands Hospital:

Start Date

2013-01

Trial ID

NCT01367236

Treatments Being Tested

standard care novel treatment

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

PHASE3

The primary objective of this study is to evaluate the efficacy of switchin...

Status

Completed

Location

Spectrum Medical Group

Start Date

2015-11-18

Trial ID

NCT02605954

Treatments Being Tested

E/C/F/TAF ABC/3TC Third Antiretroviral Agent

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

The researchers are involved in a phase II, randomized, two-arm study, comp...

Status

Completed

Location

Rockefeller University

Start Date

2007-10

Trial ID

NCT00525733

Treatments Being Tested

darunavir 800 mg FTC 200 mg/TDF 300mg Maraviroc Raltegravir Ritonavir 100 mg

Previous Next